MicroRNA-17 ∼ 92 is required for nephrogenesis and renal function

Journal of the American Society of Nephrology

Volumn 25, Issue 7, 2014, Pages 1440-1452

  Marrone, April K ^a   Stolz, Donna B ^a   Bastacky, Sheldon I ^a,b   Kostka, Dennis ^a   Bodnar, Andrew J ^a   Ho, Jacqueline ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 17 92; UNCLASSIFIED DRUG; MIRN17 92 MICRORNA, MOUSE; MIRN17-92 MICRORNA, MOUSE;

ALBUMINURIA; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; GENE EXPRESSION; GLOMERULOSCLEROSIS; KIDNEY DEVELOPMENT; KIDNEY FUNCTION; MOUSE; NEPHROGENESIS; NEPHRON; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; ANIMAL; CHRONIC KIDNEY FAILURE; FEMALE; GENETIC RENAL DISEASE; GENETICS AND DEVELOPMENT; KIDNEY; MALE; ORGANOGENESIS; PHYSIOLOGY; PRENATAL DEVELOPMENT;

GENETIC RENAL DISEASE; GENETICS AND DEVELOPMENT; NEPHRON;

ANIMALS; FEMALE; KIDNEY; MALE; MICE; MICRORNAS; NEPHRONS; ORGANOGENESIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84907208178     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013040390     Document Type: Article

References (52)

1. Smith JM, Stablein DM, Munoz R, Hebert D, McDonald RA: Contributions of the Transplant Registry: The 2006 Annual Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Pediatr Transplant 11: 366-373, 2007
2. Little MH, McMahon AP: Mammalian kidney development: Principles, progress, and projections. Cold Spring Harb Perspect Biol 4: 4, 2012
3. Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell 136: 215-233, 2009
4. Ho J, Pandey P, Schatton T, Sims-Lucas S, Khalid M, Frank MH, Hartwig S, Kreidberg JA: The pro-apoptotic protein Bim is a micro- RNA target in kidney progenitors. J AmSoc Nephrol 22: 1053-1063, 2011
5. Ho J, Ng KH, Rosen S, Dostal A, Gregory RI, Kreidberg JA: Podocytespecific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol 19: 2069-2075, 2008
6. Patel V, Hajarnis S, Williams D, Hunter R, Huynh D, Igarashi P: Micro- RNAs regulate renal tubule maturation through modulation of Pkd1. J Am Soc Nephrol 23: 1941-1948, 2012
7. Nagalakshmi VK, Ren Q, PughMM, ValeriusMT, McMahon AP, Yu J: Dicer regulates the development of nephrogenic and ureteric compartments in the mammalian kidney. Kidney Int 79: 317-330, 2011
8. Harvey SJ, Jarad G, CunninghamJ, Goldberg S, Schermer B, Harfe BD, McManusMT, Benzing T, Miner JH: Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol 19: 2150-2158, 2008
9. Shi S, Yu L, Chiu C, Sun Y, Chen J, Khitrov G, Merkenschlager M, Holzman LB, Zhang W, Mundel P, Bottinger EP: Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J AmSoc Nephrol 19: 2159-2169, 2008
10. Sequeira-Lopez ML, Weatherford ET, Borges GR, Monteagudo MC, Pentz ES, Harfe BD, Carretero O, Sigmund CD, Gomez RA: The microRNA-processing enzyme dicer maintains juxtaglomerular cells. J Am Soc Nephrol 21: 460-467, 2010
11. Wei Q, Bhatt K, He HZ, MiQS, Haase VH, Dong Z: Targeted deletion of Dicer from proximal tubules protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 21: 756-761, 2010
12. Zhdanova O, Srivastava S, Di L, Li Z, Tchelebi L, Dworkin S, Johnstone DB, Zavadil J, Chong MM, Littman DR, Holzman LB, Barisoni L, Skolnik EY: The inducible deletion of Drosha and microRNAs in mature podocytes results in a collapsing glomerulopathy. Kidney Int 80: 719-730, 2011
13. Lu Y, Thomson JM, Wong HY, Hammond SM, Hogan BL: Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol 310: 442-453, 2007
14. Danielson LS, Park DS, Rotllan N, Chamorro-Jorganes A, Guijarro MV, Fernandez-Hernando C, Fishman GI, Phoon CK, Hernando E: Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis. FASEB J 27: 1460-1467, 2013
15. Li Y, Vecchiarelli-Federico LM, Li YJ, Egan SE, Spaner D, Hough MR, Ben-David Y: The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. Blood 119: 4486-4498, 2012
16. Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, Hammond SM, MacPherson D: miR-17∼92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev 25: 1734-1745, 2011
17. de Pontual L, Yao E, Callier P, Faivre L, Drouin V, Cariou S, Van Haeringen A, Geneviève D, Goldenberg A, OufademM, Manouvrier S, Munnich A, Vidigal JA, Vekemans M, Lyonnet S, Henrion-Caude A, Ventura A, Amiel J: Germline deletion of themiR-17;92 cluster causes skeletal and growth defects in humans. Nat Genet 43: 1026-1030, 2011
18. Celli J, van Bokhoven H, Brunner HG: Feingold syndrome: Clinical review and genetic mapping. Am J Med Genet A 122A: 294-300, 2003
19. Marcelis CL, Hol FA, Graham GE, Rieu PN, Kellermayer R, Meijer RP, Lugtenberg D, Scheffer H, van Bokhoven H, Brunner HG, de Brouwer AP: Genotype-phenotype correlations in MYCN-related Feingold syndrome. Hum Mutat 29: 1125-1132, 2008
20. Ventura A, Young AG, WinslowMM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, Jaenisch R, Sharp PA, Jacks T: Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132: 875-886, 2008
21. Kobayashi A, Valerius MT, Mugford JW, Carroll TJ, Self M, Oliver G, McMahon AP: Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. Cell Stem Cell 3: 169-181, 2008
22. Self M, Lagutin OV, Bowling B, Hendrix J, Cai Y, Dressler GR, Oliver G: Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney. EMBO J 25: 5214-5228, 2006
23. Torres M, Gómez-Pardo E, Dressler GR, Gruss P: Pax-2 controls multiple steps of urogenital development. Development 121: 4057-4065, 1995
24. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R: WT-1 is required for early kidney development. Cell 74: 679-691, 1993
25. Boyle S, Shioda T, Perantoni AO, de Caestecker M: Cited1 and Cited2 are differentially expressed in the developing kidney but are not required for nephrogenesis. Dev Dyn 236: 2321-2330, 2007
26. McCright B, Lozier J, Gridley T: A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 129: 1075-1082, 2002
27. Fujii T, Pichel JG, Taira M, Toyama R, Dawid IB, Westphal H: Expression patterns of the murine LIM class homeobox gene lim1 in the developing brain and excretory system. Dev Dyn 199: 73-83, 1994
28. Madisen L, Zwingman TA, Sunkin SM, Oh SW, Zariwala HA, Gu H, Ng LL, Palmiter RD, HawrylyczMJ, Jones AR, Lein ES, Zeng H: A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci 13: 133-140, 2010
29. Ranji N, Sadeghizadeh M, Shokrgozar MA, Bakhshandeh B, Karimipour M, Amanzadeh A, Azadmanesh K: MiR-17-92 cluster: An apoptosis inducer or proliferation enhancer. Mol Cell Biochem 380: 229-238, 2013
30. Cloonan N, BrownMK, Steptoe AL, Wani S, ChanWL, Forrest AR, Kolle G, Gabrielli B, Grimmond SM: The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol 9: R127, 2008
31. Yin R, Bao W, Xing Y, Xi T, Gou S: MiR-19b-1 inhibits angiogenesis by blocking cell cycle progression of endothelial cells. Biochem Biophys Res Commun 417: 771-776, 2012
32. Patel V, Williams D, Hajarnis S, Hunter R, Pontoglio M, Somlo S, Igarashi P: miR-17∼92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. Proc Natl Acad Sci U S A 110: 10765-10770, 2013
33. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, Boldrini R, DonfrancescoA, Federici V, GiacominiP, Peschle C, FruciD:Antagomir- 17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE 3: e2236, 2008
34. Wong P, Iwasaki M, Somervaille TC, Ficara F, Carico C, Arnold C, Chen CZ, Cleary ML: The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res 70: 3833-3842, 2010
35. Gibcus JH, Kroesen BJ, Koster R, Halsema N, de Jong D, de Jong S, Poppema S, Kluiver J, Diepstra A, van den Berg A: MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma. J Pathol 225: 609-617, 2011
36. Roselli S, GribouvalO, Boute N, Sich M, Benessy F, Attié T, GublerMC, Antignac C: Podocin localizes in the kidney to the slit diaphragm area. Am J Pathol 160: 131-139, 2002
37. Vaughan MR, Quaggin SE: How do mesangial and endothelial cells form the glomerular tuft? J Am Soc Nephrol 19: 24-33, 2008
38. Bejarano F, Bortolamiol-Becet D, Dai Q, Sun K, Saj A, Chou YT, Raleigh DR, Kim K, Ni JQ, Duan H, Yang JS, Fulga TA, Van Vactor D, Perrimon N, Lai EC: A genome-wide transgenic resource for conditional expression of Drosophila microRNAs. Development 139: 2821-2831, 2012
39. Kloosterman WP, Lagendijk AK, Ketting RF, Moulton JD, Plasterk RH: Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS Biol 5: e203, 2007
40. Smibert P, Lai EC: Lessons from microRNA mutants in worms, flies and mice. Cell Cycle 7: 2500-2508, 2008
41. Miska EA, Alvarez-Saavedra E, Abbott AL, Lau NC, Hellman AB, McGonagle SM, Bartel DP, Ambros VR, Horvitz HR: Most Caenorhabditis elegans microRNAs are individually not essential for development or viability. PLoS Genet 3: e215, 2007
42. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K: Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9: 405-414, 2008
43. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K: MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 113: 396-402, 2009
44. Olive V, Jiang I, He L:mir-17-92, a cluster ofmiRNAs in the midst of the cancer network. Int J Biochem Cell Biol 42: 1348-1354, 2010
45. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclindependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994
46. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA: Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci U S A 96: 1002-1007, 1999
47. Kavurma MM, Khachigian LM: Sp1 inhibits proliferation and induces apoptosis in vascular smooth muscle cells by repressing p21WAF1/ Cip1 transcription and cyclin D1-Cdk4-p21WAF1/Cip1 complex formation. J Biol Chem 278: 32537-32543, 2003
48. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847-862, 1997
49. Tsuchida A, Ohno S, Wu W, Borjigin N, Fujita K, Aoki T, Ueda S, Takanashi M, Kuroda M: miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci 102: 2264-2271, 2011
50. Moeller MJ, Sanden SK, Soofi A, Wiggins RC, Holzman LB: Podocytespecific expression of cre recombinase in transgenic mice. Genesis 35: 39-42, 2003
51. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25: 1105-1111, 2009
52. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol 11: R106, 2010